



-1- BASIC DOC.-

UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification:

C07F 9/65, A61K 31/675

A1

(11) International Publication Number:

WO 88/05438

(43) International Publication Date:

28 July 1988 (28.07.88)

(21) International Application Number: PCT/US87/03446

(22) International Filing Date: 23 December 1987 (23.12.87)

(31) Priority Application Number: 005,471

(32) Priority Date: 20 January 1987 (20.01.87)

(33) Priority Country: US

(71) Applicant: SRI INTERNATIONAL [US/US]; 333 Ravenswood Avenue, Menlo Park, CA 94025 (US).

(72) Inventors: REIST, Elmer, J.; 581 Berkeley Avenue, Menlo Park, CA 94025 (US). STURM, Priscilla, A.; 1549 Montalto Drive, Mountain View, CA 94040 (US).

(74) Agents: CHEN, John, Y.; SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025 (US) et al.

(81) Designated States: DE, FR (European patent), GB, IT (European patent), JP, NL, SE.



Published

With international search report.

With amended claims.

08/900,746

(54) Title: ANTIVIRAL AGENTS



(57) Abstract

Certain open chain purine nucleoside phosphonate derivatives have antiviral activity against the Herpes group of viruses, and also show effective antiviral activity against retroviruses, including human immunodeficiency virus (HIV). These compounds have formula (1), wherein B represents a substituted or unsubstituted purine base, especially adenine or guanine and their halogenated derivatives, R1 is selected from H, methyl, hydroxymethyl, halomethyl, azidomethyl, and cyano; R2 is selected from H, methyl, hydroxymethyl, halomethyl, azidomethyl, cyano, and OH; also when R2 is OH the carbon to which it is attached may be oxidized so that the H there shown and R2 together may be =O; and n is an integer of 0-5. The compounds of the invention further include the pharmaceutically acceptable mono- and dibasic salts and the mono- and diesters of the phosphonate moiety and the acid addition salts of the murine-substituted purines. In addition, when R1 or R2 is -CH₂OH, or when R2 is OH, the acyl (1-6C) esters of these alcohols are included in the invention. Further, when n is 0, 1, or 2 and R1 is CH₂OH, the compounds of formula (1) include the cyclic forms wherein formal dehydration between R1 and one of the -OH groups on the phosphonate results in compounds of formula (1a) and their corresponding salts and esters.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

5

ANTIVIRAL AGENTSField of the Invention

10 The invention relates to nucleotide analogs which are antiviral agents. Specifically, it relates to acyclic purine phosphonate nucleotide analogs which are effective against both herpes-type virus and against RNA retroviruses such as HTLV-III (HIV).

15

Background of the Invention

 There are five known herpes-type viruses which affect human beings: herpes zoster (chicken pox), herpes simplex virus I & II (cold sores and genital herpes),
20 cytomegalovirus (cytomegalic inclusion disease), and Epstein-Barr virus (mononucleosis). The herpes viruses are medium-sized viruses containing double-stranded DNA. The nucleocapsid is about 100 nm in diameter and is surrounded by a lipid containing envelope. The virion
25 is 150-200 nm in diameter, and permits latent infections which last for the life span of the host even when antibodies are present.

 A very different group of virus particles is the RNA virus group. Of particular interest within this
30 group are the retroviruses which include most tumor virions, including human T-cell leukemia virus (HTLV III), now designated human immunodeficiency virus (HIV). HIV or its close relatives are believed to be the cause of Acquired Immune Deficiency Syndrome (AIDS).

-2-

General antiviral agents are numerous. Several nucleoside analogs, such as iododeoxyuridine and 5-E-bromovinyldeoxyuridine, are believed to act only
5 after conversion by viral thymidine kinase (but not by host TK) to the nucleotide form, which is then converted to the triphosphate and incorporated into the viral DNA, thus inhibiting its replication. These analogs are ineffective in certain herpes strains which are TK⁻, and
10 even TK⁺ strains resistant to certain specific members of this class of agents have been reported (Field, H., et al, J Infect Disease (1981) 143:281; Hirano, A., et al, Acta Virol (1979) 23:226). It would not be expected that agents which work by this mechanism would be
15 effective against RNA viruses.

The antiviral agents of the present invention are acyclic nucleotide analogs which are phosphonates rather than phosphates. A large number of phosphonate analogs of nucleotides are described by Engel, R., Chem
20 Reviews (1977) 11:(3)349-367. Phosphonate compounds which are direct cyclic nucleotide analogs are also disclosed in U.S. 3,560,478; German Patent Application DE3,045,375VA1, published 1 July 1982; U.S. 3,446,793; British Patent 1,243,213; German Patent Application
25 2,009,834 published 17 September 1970 and in Holman, J., et al, Liebigs Annalen Chem (1984) 98-107; Hampton, A., et al, Biochemistry (1973) 12:1730-1736; Jones, G.H., et al, J Am Chem Soc (1968) 90:5337-5338; Montgomery, J.A., et al, J Med Chem (1979) 22:109-111 and British Patent
30 1,243,214. In general, in the foregoing disclosures, the utility of the phosphonates is believed to reside in their structure being analogous to that of the nucleotides combined with enhanced stability due to the phosphonate moiety. In general, it is suggested that

-3-

they are useful for whatever pharmacological purposes the corresponding nucleotides would serve.

For example, Montgomery, J., et al, J Med Chem (supra), suggest that the phosphonate analogs may be useful as cytotoxic agents analogous to the commonly used chemotherapeutic drug 5-fluorouracil by virtue of a similar ability to inhibit the essential enzyme thymidilate synthetase, essential for DNA synthesis. This enzyme is inhibited actually by the anabolic product of 5-fluorouracil, the corresponding monophosphate.

All of the foregoing referenced compounds retain the furanose cyclic structure of the ribose or deoxyribose. Nucleoside analogs in which the cyclic furanose structure is replaced by an open chain are well known antiviral agents. French Patent Application Publication No. 2,381,781 discloses these acyclic purine nucleosides and nucleotides; similar compounds are disclosed in EPO Application Publication Nos. 0049072 and 0074306. Antiviral activity of some of these compounds with regard to herpes simplex virus is confirmed, for example, by Kelley, J.L., et al, J Med Chem (1981) 34:1528-1531.

St. Clair, M.H., et al, Antimicrob Agents Chemother (1980) 18:741-745, as reported in Chem Abstracts (1981) 94:26701v, reported that virus strains sensitive to acyclovir (9-(2-hydroxyethoxymethyl) guanine) induced production of DNA polymerases which were sensitive to its triphosphate. The same group, in a report by Bauer, D.J., et al, Dev Antiviral Therapy (1980) 43:51, as reported in Chem Abstracts (1981) 94:167716r disclose that acyclovir is effective in vitro against Varicella-Zoster, Epstein-Barr virus, cytomegalovirus, and "B" virus, and postulate that it

provides its antiviral activity by being a substrate for phosphorylation by a viral thymidine kinase, such as that specified by the herpes virus, and, in the
5 resulting triphosphate form, inhibits herpes virus DNA polymerase.

It has now been found that a series of phosphonates containing open chain ethers in lieu of ribose or deoxyribose residues in analogs of purine
10 nucleosides are effective as cytotoxic agents, both against herpes-type DNA virus, for example, cytomegalovirus, and against RNA virus, for example, HIV. While these analogs appear similar to acyclovir in general chemical structure, they actually are not, since
15 the phosphonate compounds are markedly different from the nonphosphorylated acyclovir. It is also clear that the mechanism of action for the compounds of the invention in preventing proliferation of viral infection cannot be the same as that for acyclovir, since
20 phosphorylation by viral thymidine kinase cannot occur.


After the date of the disclosure herein, publications have appeared disclosing anti-herpes activity of 9-(3-phosphono-1-propoxymethyl) guanine (EPO Publication 0173,624, published 3 May 1986) and
25 9-(3-phosphono-1-hydroxymethyl-1-propoxymethyl) guanine (Duke, A.E., et al., Antiviral Res (1986) 6:299-308; Prisbe, E.J., et al., J Med Chem (1986) 29:671-675).

Disclosure of the Invention

30 The invention provides a class of open chain alkoxymethyl nucleoside analog phosphonates which are potent antiviral agents against both herpes-type, such as cytomegalovirus, and RNA retrovirus type infections. These compounds are apparently able to penetrate the infected cell and successfully inactivate the virus.


-5-

Accordingly, in one aspect, the invention is directed to compounds of the formula:



wherein B represents a substituted or
 10 unsubstituted purine base, especially adenine or guanine and their halogenated derivatives, R1 is selected from H, methyl, hydroxymethyl, halomethyl, azidomethyl, and cyano; R2 is selected from H, methyl, hydroxymethyl, halomethyl, azidomethyl, cyano, and OH; also when R2 is
 15 OH the carbon to which it is attached may be oxidized so that the H there shown and R2 together may be =O; and n is an integer of 0-5. The compounds of the invention further include the pharmaceutically acceptable monoand dibasic salts and the mono- and diesters of the
 20 phosphonate moiety and the acid addition salts of the amino-substituted purines. In addition, when R1 or R2 is -CH₂OH, or when R2 is OH, the acyl (1-6C) esters of these alcohols are included in the invention.

Further, when n is 0, 1, or 2 and R1 is CH₂OH,
 25 the compounds of Formula 1 include the cyclic forms wherein formal dehydration between R1 and one of the -OH groups on the phosphonate results in compounds of the formula:



and their corresponding salts and esters.

In other aspects, the invention relates to pharmaceutical compositions containing the compounds of Formula 1 or 1a and to methods of treating or preventing herpes-type and RNA retrovirus infections by use of the compounds of Formula 1 (or 1a) or these compositions.

Modes of Carrying Out the Invention

10 A. Description of the Compounds of the Invention

The compounds of the invention may be in the form of phosphonic acids, esters, or pharmaceutically acceptable salts. In addition, the compounds may be used as the acid addition salts of the purine base.

15 The salts of the phosphonic acid moiety are salts with inorganic or organic bases and may be the mono- or dibasic salts. Salts derived from inorganic bases include the sodium, potassium, lithium, alkaline metal, such as magnesium and calcium salts, and salts of the transition metals or of aluminum. Salts derived from ammonium, potassium, sodium, calcium and magnesium are preferred. Suitable organic bases which are nontoxic and are capable of forming salts with the phosphonic acid moiety include various amines such as ethanolamine, triethylamine, isopropylamine, and amino acids such as lysine and arginine.

25 The phosphonic acid moiety of the compounds of the invention may also be in the form of the mono- or diester. The esters will be formed from alkyl, aryl-alkyl, and aryl alcohols containing 1-8 C. Alkyl alcohols include saturated or unsaturated straight chain, branch chain, or cyclic hydrocarbyl alcohols which may be substituted with one or two additional hydroxyl substituents or contain heterocyclic rings which include N, O and/or S atoms. Such moieties

-7-


include, for example, methyl, isobutyl, n-octyl, 2-butenyl, 4-hydroxy-n-pentyl and so forth. When the alcohol is aryl or aryl-alkyl, the ester contains a phenyl substituent optionally substituted by one or two halo, alkoxy or hydroxy residues and representative groups of this class include the phenyl ester, the 3-hydroxyphenyl ester, the benzyl ester, and the 2-phenylethyl ester. Especially preferred are the alkyl (1-6C) esters.

Since the purine substituents represented by B are basic, the compounds of the invention may also be supplied as the acid addition salts which retain the biological effectiveness and properties of the free bases and which are not otherwise undesirable. These salts may be formed from inorganic acids such as hydrochloric, hydrobromic acid or sulfuric acid, or from organic acids such as acetic, propionic, glycolic, oxalic, malonic, succinic, tartaric, cinnamic, methane sulfonic, p-toluene sulfonic, salicylic, and so forth.

R1 is selected from hydrogen, methyl, substituted methyl and cyano. Substituted methyl groups include CH₂OH, CH₂N₃, CH₂Cl, CH₂Br, CH₂F, and CH₂I. R2 is selected from this same group, but can, in addition, be OH; or when -OH, can be in oxidized form so that R2 in combination with H attached to the same C become =O. Further, when R2 or R1 is CH₂OH, or R2 is OH, the acyl esters (1-6C), such as the esters of acetic, proprionic, butyric, and hexanoic acids, are also included.

The purine moieties of the invention are derived either from adenine or guanine each of which has a nucleus of the formula:

-8-



5

which has the numbering system shown. The numbering system will be retained herein as shown, regardless of substituents to the ring system. The bond at position 9 conjugates the acyclic or cyclic sugar derived moiety; further substitutions can be made at positions 2, 6 and 8.

For guanine the substituent at position 6 is hydroxyl (in the tautomer shown) and in adenine, -NH_2 . Guanine has -NH_2 at position 2, adenine is unsubstituted. These and their further substituted analogs are preferred embodiments of the compounds of the invention. In addition, guanine or adenine analogs having halo groups in place of the hydroxyl or amino at position 6, such as chloro or bromo in particular, are preferred. In general suitable substituents at positions 2, 6 and 8 include hydroxyl, amino and halo wherein halo is defined as fluoro, chloro, bromo, and iodo.

Preferred values for n in the compound of Formula 1 are 0-2.

Representative embodiments of the compounds of the invention include:

30

9(3'-diethylphosphono-1'-propyloxymethyl)guanine;
9(3'-diethylphosphono-1'-propyloxymethyl)adenine;

-9-

- 9(3'-di-i-propylphosphono-1'-propyloxymethyl)adenine;
9(3'-di-i-propylphosphono-1'-propyloxymethyl)guanine;
9(3'-i-propylphosphono-1'-propyloxymethyl)guanine;
5 9(3'-dibutylphosphono-1'-n-butyloxymethyl)guanine;

6-chloro-9(4'-dibutylphosphono-1'-n-butyloxymethyl)
guanine;
10 6-chloro-9(4'-dibutylphosphono-1'-n-butyloxymethyl)
adenine;

6-chloro-9(5'-phosphono-1'-n-pentyloxymethyl-1'-
chloromethyl)guanine;
15 6-chloro-9(5'-phosphono-1'-n-pentyloxymethyl-1'-
chloromethyl)adenine;

6-chloro-9(5'-phosphono-1'-n-pentyloxymethyl)adenine;
6-chloro-9(4'-phosphono-1'-n-pentyloxymethyl)adenine;
20 6-chloro-9(4'-phosphono-1'-n-pentyloxymethyl)guanine;

9(6'-phosphono-1'-n-hexyloxymethyl-1'-hydroxymethyl)
guanine;
8-bromo-9(6'-phosphono-1'-n-hexyloxymethyl-1'-
25 hydroxymethyl)guanine;
8-chloro-9(6'-phosphono-1'-n-hexyloxymethyl-1'-
hydroxymethyl)guanine;

9(6'-phosphono-1'-n-hexyloxymethyl-1'-hydroxymethyl)
30 adenine;
8-chloro-9(6'-phosphono-1'-n-hexyloxymethyl-1'-
hydroxymethyl)adenine;
8-bromo-9(6'-phosphono-1'-n-hexyloxymethyl-1'-
hydroxymethyl)adenine;

-10-

6-chloro-9(6'-phosphono-1'-n-hexyloxymethyl-1'-hydroxy
methyl)adenine;

6-chloro-9(6'-phosphono-1'-n-hexyloxymethyl-6'-keto)
5 guanine;

6-chloro-9(4'-phosphono-1'-n-pentyloxymethyl-1'-hydroxy
methyl)guanine;


6-chloro-9(5'-phosphono-1'-n-pentyloxymethyl-5'-keto)
10 adenine; and

6-chloro-9(4'-phosphono-1'-n-butyloxymethyl-4'-keto)
adenine;

and their various esters and salts as set forth above.

15 B. Preparation of the Invention Compounds

Reaction Scheme 1 shows the general method to
prepare the compounds of Formula 1.



Reaction Scheme 1

As shown in Reaction Scheme 1, treatment of
30 the intermediate alcohol, $(\text{R}'\text{O})_2\text{P}(\text{O})\text{CH}(\text{R2})(\text{CH}_2)_n$
 $\text{CH}(\text{R1})\text{OH}$, with formaldehyde in the presence of
hydrochloric acid provides the corresponding
chloromethyl ether. The purine base, B, is then
conjugated to the resulting acyclic moiety by
displacement of the chloride with purine, using, for


-11-

example, a silylated purine according to the method of Robins, et al, Can J Chem (1982) 60:547-553.

The resulting diester is, of course, a compound of the invention, that can be converted to the free acid by a modification of the method of McKenna, et al, Tet Letts (1977) 155.

The monoester is prepared by treatment of the diester with aqueous 1 N sodium hydroxide, as described by Jones and Moffatt, J Am Chem Soc (1968) 90:5337. Any 6-chloro group on the purine will simultaneously be replaced by -OH.

The intermediate alcohol is obtained by methods which depend on the nature of R1 and R2. When R1 and R2 are either both methyl or both H, this alcohol is made according to Reaction Scheme 2.




Reaction Scheme 2

Reaction Scheme 2 describes the condensation of a trialkyl phosphite, wherein R' represents alkyl, with a symmetric dibromoalkane, according to the procedure of Eberhard and Westheimer, J Am Chem Soc (1965) 87:253.

However, when R2 is H and R1 is hydroxymethyl or methyl, the required alcohol intermediate is prepared according to Reaction Scheme 3.

-12-




Reaction Scheme 3

The initial condensation of Reaction Scheme 3 is according to the method of Savignac, et al., Synth Comm (1979) 9:487. Treatment of the resulting unsaturated butyl phosphonate with meta-peroxybenzoic acid, as shown, gives the epoxide. The epoxide can then be cleaved with BF_3 etherate in glacial acetic acid to obtain an acetoxymethyl intermediate for R1 as hydroxymethyl; or can be reduced with diborane and sodium borohydride to yield R1 as methyl.

For embodiments wherein R1 is H and R2 is OH, Reaction Scheme 4 is employed to form the intermediate alcohol, derivatized to the silyl ether.

-13-



Reaction Scheme 4

25 In this process, the intermediate phosphonate is prepared as described by Gazizov, T., et al, Gen Chem USSR (1977) 47:2465, and then derivatized with alkyl chlorosilane before functionalization of the alkene to form the desired alcohol.

30 C. Interconversion of Salt and Ester Derivatives

The compounds of Formulas 1 and 1a may be prepared in their salt or ester forms, and these esters or salts can be reconverted to the free acid or free purine base.

Phosphonic Acid Salts

If desired, the free phosphonic acid may be converted to the mono- or dibasic salt form by treatment with an appropriate base. These salts are prepared by treating the corresponding free acids with at least one or at least two molar equivalents of a pharmaceutically acceptable base as set forth above. The reaction is conducted in water, alone or in combination with an inert, water miscible organic solvent at a temperature of from 0°C-100°C, preferably room temperature. Typical inert, water miscible organic solvents include methanol, ethanol and dioxane. The stoichiometry of the resulting salt is dependent on the stoichiometry of the reaction components.

The salts can be reconverted to the phosphonic acid by standard procedures, e.g. by neutralizing with an acid resin or, less preferably, with an organic acid.

Acid Addition Salts

Alternatively, acid addition salts of the purine moiety may be prepared by reacting a compound of the invention with an acid such as the organic or inorganic acids exemplified above. The free base is dissolved in an polar organic solvent such as methanol or ethanol and the acid is added at a temperature of 0-100°C, preferably at room temperature. The resulting salt either precipitates or may be brought out of solution by addition of a less polar solvent.

Conversely, the acid addition salt is reconverted to the free base by treating with suitable base.

-15-

Phosphonic Acid Esters

Desired esters of the phosphonic acid moiety may be prepared by transesterification of the phenyl esters using methods illustrated by Jones and Moffatt, J Am Chem Soc (1968) 90:5337. Although the examples below result in diethyl esters, the corresponding phenyl esters could be prepared by analogous methods by substituting phenyl phosphonate ester starting materials for the ethyl phosphonate ester starting materials illustrated.

The esters can be reconverted to the free acids by hydrogenolysis of the benzyl or hydrolysis of trimethyl silyl esters. These esters may be prepared by transesterification as above described.

Esters of R1/R2 Alcohols

These esters can result directly from the synthetic pathways illustrated below.

20 D. Utility and Administration

The compounds of this invention (including the physiologically acceptable salts and esters thereof) have antiviral activity against herpes virus forms and against RNA retroviruses. The compounds are conveniently formulated into pharmaceutical preparations composed of one or more of the compounds in association with a pharmaceutically acceptable carrier. Remington's Pharmaceutical Sciences, latest edition, by E.W. Martin (Mack Publ. Co., Easton, PA) discloses typical carriers and methods of preparation known in the art.

The compounds may be administered topically, orally, parenterally (e.g., intravenously), by intramuscular injection, or by intraperitoneal injection, or the like, depending upon the nature of the

-16-

viral infection being treated. For internal infections the compositions are administered orally or parenterally at dose levels of about 0.1 to 300 mg/kg, preferably 1.0 to 30 mg/kg of mammal body weight and can be used in humans in a unit dosage form administered one to four times daily in the amount of 1-250 mg per unit dose.

For oral administration, fine powders or granules may contain diluting, dispersing, and/or surface active agents, and may be presented in water or in a syrup, in capsules or sachets in the dry state, or in a nonaqueous solution or suspension wherein suspending agents may be included, in tablets wherein binders and lubricants may be included, or in a suspension in water or a syrup. Where desirable or necessary, flavoring, preserving, suspending, thickening, or emulsifying agents may be included. Tablets and granules are preferred oral administration forms, and these may be coated.

Alternatively, for topical infections, e.g., mouth and skin, the compositions are preferably applied to the infected part of the body of the patient topically as an ointment, cream, aerosol, or powder, preferably as an ointment or cream. The compounds may be presented in an ointment, for instance with a water soluble ointment base, or in a cream, for instance with an oil in water cream base in a concentration of from about 0.01 to 10%, preferably 0.1 to 7%, most preferably about 0.5% w/v. Additionally, viral infections of the eye, such as Herpetic keratitis, may be treated by use of a sustained release drug delivery system as is described in the art.

The exact regimen for administration of the compounds and compositions disclosed herein will necessarily be dependent upon the needs of the

-17-



individual subject being treated, the type of treatment, and, of course, the judgment of the attending practitioner.

5 E. Examples

The invention will be further described by the following nonlimiting examples.

Example 1

10 Preparation of 6-Chloro-9(3'-diethyl phosphono-1'-propyloxymethyl) Guanine



(This is not precisely a guanine derivative, since the -OH at position 6 is not present, and "B" should properly be called 2-amino-6-chloropurine; however, 6-chloroguanine is conventionally used.)

Diethyl-3-hydroxypropylphosphonate (steps 1 and 2) is prepared from diethyl-3-bromopropylphosphonate. Diethyl-3-bromopropylphosphonate (12.0 g, 46 mmol), prepared by the method of Eberhard, A., et al, J Am Chem Soc (1965) 87:253-260) was stirred with 12.0 g NaOAc·3H₂O in 125 ml DMF heated in a steam bath. The reaction was evaporated to dryness in vacuo after 2 hours and partitioned between H₂O and EtOAc, extracting

the aqueous layer five times. The ethyl acetate extract was washed once with brine, dried with Na_2SO_4 , filtered, and evaporated to dryness in vacuo to yield 9.8 g light yellow oil (89%). ^1H NMR (CDCl_3) δ 1.3 (tr, 6 H), 1.5-2.0 (m, 4 H), 2.03 (s, 3 H), 4.1 (dq, 6 H); thin-layer chromatography on SiGF developed with 2:1 EtOAc: CH_2Cl_2 gave R_f 0.30. The isolated diethyl-3-acetoxypropylphosphonate (9.8 g, 41 mmol) in 200 ml abs. EtOH was stirred with 30 ml Dowex 50 (H^+) which had been rinsed three times each with H_2O and EtOH. After 4-1/2 days at room temperature, another 10 ml of similarly prepared resin was added. Six hours later, the reaction was filtered and evaporated in vacuo. The quantitative yield of yellow oil was purified by dry column chromatography on 400 g silica packed in a 2.75 inch flat diameter nylon tube. The column was eluted with 1:9 MeOH:EtOAc and the appropriate fractions were cut and slurried with 1:1 MeOH:EtOAc. Filtration and evaporation in vacuo afforded 5.33 g (66%) pale yellow oil, which is the diethyl ester of 3-hydroxypropyl phosphonic acid. ^1H NMR (CDCl_3 , D_2O): δ 1.30 (tr, 6 H), 1.60-2.08 (m, 4 H), 3.67 (tr, 2 H), 4.13 (cq, 4 H); thin-layer chromatography on SiGF developed with 1:9 MeOH:EtOAc gave an R_f of 0.57.

Conversion to diethyl-3-chloromethoxypropyl phosphonate was according to the procedure of Kelley, J.L., et al, J Med Chem (1981) 24:1528-1531.

To 0.5 g (2.95 mmol) 2-amino-6-chloropurine, silylated and treated with $\text{Hg}(\text{CN})_2$ according to the procedure of Robins, M.J., et al, Can J Chem (1982) 60:547-553, in 40 ml benzene, was added a solution of 2.68 mmol diethyl-3-chloromethoxypropylphosphonate prepared as above. The reaction was refluxed for 2 hours, cooled, and 400 ml CHCl_3 was added. The organic

-19-

phase was washed successively with 80 ml each of aqueous saturated NaHCO_3 and 1 M aqueous KI. The organic solution was dried over Na_2SO_4 , filtered, and evaporated to 790 mg of yellow gum. A portion of this crude material was used to conduct hydrolysis experiments. The remaining material was chromatographed on a silica column. A solution of 574 mg of the crude reaction product was placed on 20 g silica packed in a column using 5:3 EtOAc:nPrOH. Elution with the same mixed solvent afforded sixteen fractions of 10-20 ml each. Fractions 7-12 were combined to yield 258 mg of a colorless oil which spontaneously crystallized. Trituration in $\text{CH}_2\text{Cl}_2 \cdot \text{Et}_2\text{O}$ afforded two crops of white solid (207 mg), mp $109-110^\circ$ (28%). A yield of 46% of the diethyl ester was obtained from a reaction performed on 45.2 mmol of the starting purine. Anal ($\text{C}_{13}\text{H}_{21}\text{ClN}_5\text{O}_4\text{P}$) C, H, N; UV λ_{max} (ϵ): pH 1, 246 (ϵ 6600), 310 (7200); pH 7, 247 (6800), 308 (7400); pH 11 247 (6600), 308 (7100); mass spectrum: m/e 377 (M^+); ^1H NMR (CDCl_3): δ 1.3 (tr, 6 H), 1.52-2.18 (m, 4 H), 3.58 (tr, 2 H), 4.09 (dq, 4 H), 5.48 (s. with broad base, 4 H), 7.89 (s, 1H). Thin-layer chromatography on SiGF developed with 5:3 EtOAc:nPrOH gave R_f 0.40.

25

Example 2Preparation of9(3'-ethylophosphono-1'-propyloxymethyl)guanine

A. 6-Chloro-9(3'-diethylphosphono-1'-propyloxymethyl) guanine (75 mg; 0.2 mmol) prepared as in Example 1 was combined with 5 ml 1 N aqueous NaOH and refluxed 1 hour. The cooled reaction was neutralized with Dowex 50X8 (pyridinium form) and filtered, rinsing liberally with water. The solution was partially

-20-

evaporated to remove pyridine and was then lyophilized. The orange-colored residue (74 mg) was redissolved in H₂O and centrifuged to remove insoluble material. The decanted solution (2 ml) was chromatographed on a 0.9 x 46 cm column of Whatman DE-52 Cellulose, HCO₃ form, using a linear gradient of one liter each H₂O and 0.2 M NH₄HCO₃ after an initial H₂O elution. Fractions (7 ml each) 43-47 yielded 25 mg (36%) of fluffy white solid after three lyophilizations. Electron impact mass spectrum (TMS derivative) showed m/e 547 (M⁺ of TMS derivative); chemical ionization mass spectrum (TMS derivative) showed m/e 548 (M⁺ + H of TMS₃ derivative). ¹H NMR (D₂O) showed δ 1.19 (tr, 3 H), 1.4-1.9 (m, 4 H), 3.59 (tr, 2 H), 3.90 (dq, 2 H), 5.47 (s, 2 H), 8.2 (brs, 1 H). Thin-layer chromatography behavior on SiGF: R_f=0.40 when developed with 7:3 CH₃CN:0.1 N aqueous NH₄Cl. Material obtained from passage through a column of Dowex 50X8 (H⁺) had a formula of (C₁₁H₁₈N₅O₅P·H₂O) Calc: C-37.82% H-5.77%, N-20.05. Found: C-38.27%, H-5.84%, N-19.65%. A UV spectrum was run on the material and showed UV λ_{max} (ε): pH 1, 255 (11,900), 278 shoulder; pH 7, 252 (12,800) 271 shoulder; pH 11, 257 (10,700) 267 shoulder.

(The hydrolysis to the monoester, simultaneously effects dehalogenation of the purine ring.)

B. In an improved procedure, a mixture of 6-chloro-9(3'-diethylphosphono-1'-propyloxymethyl) guanine (4.27g, 11.3 mmol) and 1N aqueous NaOH (200ml) was gently refluxed for 1 hour. The cooled reaction was neutralized and desalted with Dowex 50 X 8 (pyridinium form). The resin was removed by filtration, rinsing thoroughly with water. The aqueous filtrates were

-21-

partially evaporated to remove pyridine and then lyophilized. A solution of the residue (3.68g) in H₂O (30 ml, pH 8) was chromatographed on a bed of DEAE-Cellulose (Whatman DE 52, HCO₃⁻ form, 2.5 x 100 cm). After an initial water wash to constant baseline, the column was eluted with a linear gradient of two liters each H₂O and 0.1N NH₄HCO₃. Fractions (20 ml each) 89-139 were combined and lyophilized to constant weight (2.25g).

At 0°C, a solution of this material in a minimum amount of H₂O plus an equal amount of EtOH was treated with cold 1N HCl to pH 3.5 to yield 1.31g (34%) of the title compound as a fine white solid. Electron impact mass spectrum (TMS derivative) showed m/e 547 (M⁺ of TMS₃ derivative); chemical ionization mass spectrum (TMS derivative) showed m/e 548 (M⁺+H of TMS₃ derivative); chemical ionization mass spectrum on underivatized compound gave m/e 332 (M⁺+H). Further characterization by ¹H NMR (DMSO-d₆) showed δ 1.17 (tr, 3H), 1.3-1.8 (m, 4H), 3.48 (tr, 2H), 3.85 (dq, 2H), 5.30 (s, 2H), 6.46 (br s, 2H), 7.79 (s, 1H). An ultraviolet spectrum showed UV λ_{max} (ε): pH 1, 254 (12,800) 275 shoulder; pH 7, 252 (13,200) 272 shoulder; pH 11, 257 (11,400) 267 shoulder. The material had a formula of (C₁₁H₁₈N₅O₅P • 1/2 H₂O). Calc: C-38.82%, H-5.63%, N-20.58%. Found: C-38.52%, H-5.90%, N-20.34%. Thin layer chromatography behavior on SiGF: R_f=0.40 when developed with 7:3 CH₃CN:0.1 N NH₄Cl.

30

Example 3

Conversion of the Monoester to Free Acid: 9(3'-Phosphono-1'-propyloxymethyl)guanine

In a modification of the procedure of McKenna et al, Tet. Letters, (1977) 155, to a stirring mixture

-22-


of 200 mg (0.57 mmol) 9(3'-ethylphosphono-1'-propyloxy methyl)guanine in CHCl_3 (8.3 ml) and hexamethyldi-silazane (8.3 ml) at room temperature was added 0.61 ml (4.60 mmol) bromotrimethylsilane. After 72 hours, the mixture was evaporated to dryness, slurried with H_2O , and filtered, rinsing with acetone. A white solid (125 mg) was obtained. ^1H NMR indicated no ethyl groups, and thin-layer chromatography on SiGF (7:3 CH_3CN : 0.1 N NH_4Cl) revealed a single spot at R_f 0.20. The sodium salt was generated from Dowex 50 x 2 (Na^+) to yield 114 mg (58%) white solid after lyophilization. ^1H NMR ($\text{DMSO}-d_6 + \text{D}_2\text{O}$) showed δ 1.68 (m, 4H), 3.60 (tr, 2H), 5.48 (s, 2H), 7.96 (s, 1H). An ultraviolet spectrum showed λ_{max} (ϵ): pH 1, 256 (10,800) 278 shoulder; pH 7, 256 (11,800) 270 shoulder; pH 11, 256 (10,200) 268 shoulder. Microanalysis afforded the formula $(\text{C}_9\text{H}_{13}\text{N}_5\text{O}_5\text{P} \cdot \text{Na} \cdot \text{H}_2\text{O})$ Calc: C-31.49%, H-4.41%, N-20.41%, P-9.02%. Found: C-31.52%, H-4.55%, N-20.10%, P-8.21%; mass spectrum m/e 591 (M^+ for TMS_4 derivative).

20

25

30

-23-

Example 4Preparation of6-Chloro-9(7'-diethylphosphono-1'-heptoxymethyl)guanine

Diethyl 7-chloromethoxyheptylphosphonate was prepared from 1,7-dibromoheptane and triethylphosphite in a manner analogous to that of Example 1. It was reacted with silylated 2-amino-6-chloropurine, and mercuric cyanide as described for the preparation of 6-chloro-9(3-diethylphosphono-1-propyloxymethyl)guanine in Example 1 to give 32% of product as a colorless gum. UV λ_{\max} (ϵ): pH 1 -246 nm (6970), 310 nm (7190); pH 7 -247 nm (6620), 310 nm (7180); pH 11 -246 nm (6660), 309 nm (7140); ¹H NMR (CDCl₃) δ 1.1-1.9 (m, 18 H), 3.48 (t, 2 H), 4.10 (dq, 4 H), 5.47 (s, 2 H), 5.88 (s, 2 H), 7.93 (s, 1 H). Thin-layer chromatography on SiGF gave R_f 0.15 using ethyl acetate:ethanol (100:1); analysis shows C₁₇H₂₉ClN₅O₄P · H₂O.

Example 5Conversion to the Monoester:9(7'-ethylphosphono-1'-heptyloxymethyl)guanine

6-Chloro-9(7'-diethylphosphono-1-heptyloxy methyl) guanine of Example 4 was hydrolyzed by refluxing 1 N aqueous sodium hydroxide for 4 hours and isolated in 30% yield as described for the preparation of 9-(3'-ethyl phosphono-1'-propyloxymethyl)guanine (Example 2). It had R_f 0.5 on SiGF using acetonitrile:0.1 N aqueous


ammonium chloride, (7:3) . Proton NMR (D₂O): δ=1.1 1.5 (m, 15 H), 3.5 (t, 2 H), 3.90 (dq, 2 H), 5.45 (s, 2 H). UV λ_{max} (ε): pH 7, 252 (12,200). Mass spectrum m/e 603 (M⁺ for TMS₃ derivative).

5


Example 6

Preparation of 9(3'-ethylphosphono-1'-hydroxymethyl-1'-propyloxymethyl)guanine

10




15



20

silated
6-chloroguanine (6-Cl-G)

25



A. Preparation of Diethyl-3,4-epoxybutanephosphonate.

Diethyl-3,4-epoxybutanephosphonate was synthesized according to the procedure of Savignac et al., Syn Comm (1979) 7:487. In several syntheses, oxidation of the intermediate olefin compound produced a contaminating white solid which was removed by filtration of the crude, neat reaction product and


30

- 25 -

rinsing the solid with ice cold CH_2Cl_2 . Evaporation of the filtrate and distillation of the residue gave the epoxide in 75% yield.

5 B. Preparation of Diethyl 3-hydroxy-4-acetoxy butyl
phosphonate.

To a stirring solution of 2.51 g (12 mmol) diethyl-3,4-epoxybutanephosphonate in glacial acetic acid (10 ml) at room temperature in a dry, inert atmosphere was added 0.2 ml BF₃ etherate. After stirring 1 hour, H₂O (20 ml) was added; the reaction was stirred 10 minutes and evaporated in vacuo. H₂O was twice added and reevaporated to azeotrope HOAc. The residual syrup was partitioned between saturated aqueous NaHCO₃ (30 ml) and Et₂O (20 ml). The aqueous phase was extracted with CHCl₃ (3 x 20 ml). The CHCl₃ extract was washed once with H₂O (10 ml), dried (Na₂SO₄), filtered, and evaporated to obtain 2.15 g (67%) colorless oil. ¹H NMR (CDCl₃ + D₂O) spectral data indicated this material to be 85% pure as measured by the ratio of the -OCOCH₃ singlet at 2.1δ to the (CH₃CH₂O)₂PO-triplet at 1.32δ. GC/MS data on the TMS derivative indicated one major component whose fragmentation pattern contained an extremely intense absorbance at m/e 267 with only small absorbance seen at m/e 237. This information is supportive of the structure for the desired isomer



30

-27-

248, 311; TOD₂₄₈ 14.4/mg (TOD₂₄₈ 16.9/mg for 6-chloro-9(3'-diethylphosphono-1'-propyloxymethyl)-guanine from Example 1.

5 D. Conversion to the Monoester and Hydrolysis:

9(3'-ethylphosphono-1'-hydroxymethyl-1'-propyloxymethyl)guanine

The hydrolysis of 7.95 g (17.7 mmol) 6-chloro-9(3'-diethylphosphono-1'-acetoxymethyl-1'-propyloxymethyl)guanine with 1 N aqueous NaOH (130 ml) was conducted as in Example 3B for the synthesis of 9(3'-ethyl phosphono-1'-propyloxymethyl)guanine. Material isolated from DEAE-Sephadex (2.5 x 97 cm A-25, HCO₃⁻) chromatography required purification on a second similar column again using a linear gradient of H₂O and 0.1 N NH₄HCO₃ (2.0 liters each). Examination of fractions by HPLC (Vydac TP21854, 1% CH₃CN in 0.0125N triethylammonium formate, pH 3, 2 ml/min, 252λ), of ultraviolet spectra and of the total optical density (TOD^{PH7}₂₅₂) relative to the weight obtained after several lyophilizations allowed one to obtain two pure fractions of 9(3'-ethylphosphono-1'-hydroxymethyl-1'-propyloxymethyl) guanine (1.0 g each, 29%, 36 TOD^{PH7}₂₅₂/mg), one of which contained an isomer ratio of 3:2 by HPLC and the second, an isomer ratio of 1:1. Microanalysis of the latter sample gave the formula (C₁₂H₂₀N₅O₆P · 1/4 NH₃ · 1 H₂O). Calc: C-37.57%, H-5.98%, N-19.17%. Found: C-37.47%, H-5.50%, N-19.16%. UV λ_{max} (ε): pH 1, 256 (12,400) 276 shoulder; pH 7, 252 (13,500) 270 shoulder; pH 11, 256 (11,800) 266 shoulder. ¹H NMR (D₂O): δ 1.22 (d tr, 3H), 1.35-1.88 (m, 4H), 3.48-4.0 (m, 5H), 5.52 (d, 2H), ~7.9 (very broad singlet, 1H). Thin-layer chromatography on SiGF: R_f 0.32 (7:3 CH₃CN:0.1 N NH₄Cl).

Example 7

Preparation of 9(3'-Phosphono-1'-hydroxymethyl-1'-propyloxymethyl)guanine

5 9(3'-Ethyl phosphono-1'-hydroxymethyl-1'-propyl oxymethyl)guanine (204 mg, 0.52 mmol of the partial ammonium salt) was treated with bromotrimethyl silane (0.8 ml, 6.13 mmol) in a procedure similar to the synthesis of 9(3'-phosphono-1'-propyloxymethyl) guanine
10 of Example 4. To aid in solubilization of the starting material in the reaction medium, 1,5-diazabicyclo[5.4.0]undec-5-ene (0.078 ml, 0.52 mmol) was added. After stirring overnight at room temperature, the mixture was evaporated to dryness. The residue was dissolved
15 readily in 3 ml H₂O and was treated with several drops of 1 M HCl to acidity and reevaporated. Trituration with EtOH followed by filtration yielded 161 mg off-white solid (93%). Thin-layer chromatography on SiGF (7:1:2, iPrOH:NH₄OH:H₂O) gave R_f 0.18. UV λ_{max} :
20 pH 1, 256, 278 shoulder; pH 7, 252, 272 shoulder; pH 11, 255, 268 shoulder. ¹H NMR (D₂O) δ : 1.55-1.85 (m, 4H), 3.5-3.95 (m, 3H), 5.58 (d), 7.95 (br s, 1H). Mass spectrum m/e 693 (M⁺ for TMS₅ derivative).

25

Example 8

Preparation of 9(3'-phosphono-1'-hydroxymethyl-1'-propyloxymethyl)guanine cyclic ester

In a procedure similar to that of Khorana, H.G., et al in J Am Chem Soc (1961) 82:698, a mixture of
30 0.011 g (0.033 mmol) 9(3'-phosphono-1'-hydroxymethyl-1'-propyloxymethyl)guanine (Example 9) in 6 ml dry pyridine was treated with 0.010 g (0.034 mmol) N',N'-dicyclohexyl-4-morpholine carboxamidine at reflux. After solution was complete, a hot solution of 0.012 g

-29-

(0.058 mmol) dicyclohexylcarbodiimide in 4 ml pyridine was added in a single portion, and the solution was heated at gentle reflux for 2-1/2 hours. The reaction was evaporated to dryness. The residue was triturated in H₂O and filtered. The filtrate was evaporated to dryness, then solubilized in MeOH. Thin-layer chromatography on SiGF showed a single spot at R_f=0.70 using iPrOH:NH₄OH:H₂O (7:1:2) R_f=0.41 using CH₃CN:0.01 N NH₄Cl (7:3), and R_f=0.78 using MeOH. UV λ_{max}: pH 7, 251, 275 shoulder. Mass spectrum m/e 531 (M⁺ for TMS₃ derivative).

Example 9

Preparation of 8-Bromo-9 (3' ethylphosphono-1'-propyloxymethyl) guanine

A stirring mixture of 97 mg (0.286 mmol) 9(3'-ethylphosphono-1'-propyloxymethyl) guanine, prepared in Example 2 in H₂O (5 ml) was treated with a saturated Br₂ in H₂O solution according to the procedure of Robins, M.J., et al., J Med Chem (1984) 27:1486-1492 until the bromine color persisted (3-4 ml). After stirring 30 minutes at room temperature, the color was discharged with crystals of NaHSO₃. The reaction was filtered, then washed with H₂O and EtOH, to collect 99 mg (87%) white solid which appeared to be homogenous by thin layer chromatography using SiGF: R_f=0.33 using CH₃CN:0.1N NH₄Cl(7:3). ¹H NMR (DMSO-d₆): δ 1.19 (tr, 3H), 1.3-1.9 (m, 4H), 3.53 (tr, 2H), 3.92 (dq, 2H), 5.33 (s, 2H), 6.68 (br s, 2H). UV λ_{max} (ε): pH 1, 260 (16,400); pH 7, 260 (16,400), pH 11, 269 (13,600).

HPLC examination of the compound on a Vydac TP-21854 column (4.6 x 250 mm) with a 15 min non-linear gradient of 0 to 100% 'B' in 'A', where 'A' is 0.0125N Et₃N·HCO₂H, pH 3.0 and B is 5% aqueous CH₃CN (program #8

-30-

on Waters Model 660 solvent programmer) indicated about
5% starting material. Chromatography on DEAE sephadex
as related in Example 1 using a linear gradient of water
and 0.1N $\text{NH}_4 \text{HCO}_3$ yielded product title compound free of
5 starting material.

10

15

20

25

30

- 31 -

Example 10

Preparation of 9(3'-Ethylphosphono-3'-Hydroxy-1'-propyloxymethyl)guanine

5

1. EtOH

2. $\text{CH}_2=\text{CHCHO}$

$(\text{EtO})_2\text{PCl} \longrightarrow \text{CH}_2=\text{CHCH}(\text{OH})\text{C}(=\text{O})\text{P}(\text{OEt})_2 \longrightarrow \text{CH}_2=\text{CHCH}(\text{OSi}(\text{CH}_3)_2\text{tBu})\text{C}(=\text{O})\text{P}(\text{OEt})_2$

10

$\text{HOCH}_2\text{CH}_2\text{CH}(\text{OSi}(\text{CH}_3)_2\text{tBu})\text{C}(=\text{O})\text{P}(\text{OEt})_2$

15

$\text{CH}_2\text{O}, \text{HCl}$

$\text{ClCH}_2\text{OCH}_2\text{CH}_2\text{CH}(\text{OSiMe}_2\text{tBu})\text{C}(=\text{O})\text{P}(\text{OEt})_2$

20

silated
6-chloroguanine (6-Cl-G)

$6\text{-Cl-G-CH}_2\text{OCH}_2\text{CH}_2\text{CH}(\text{OSi}(\text{CH}_3)_2\text{tBu})\text{C}(=\text{O})\text{P}(\text{OEt})_2$

25

$\text{G-CH}_2\text{OCH}_2\text{CH}_2\text{CH}(\text{OH})\text{C}(=\text{O})\text{POEt}_2$

A. Preparation of Diethyl 1-t-butyl dimethylsilyloxy
allyl phosphonate.

A solution of 68.8 g (0.355 mole) diethyl 1-hydroxyallyl phosphonate, prepared as reported by

Gazizov et al, J Gen Chem USSR (1977) 47:2465, (Eng. Trans., p. 2253), in 120 ml dry DMF was combined with 60.44 g (0.888 mole) imidazole and treated with 63.87 g (0.424 mole) t-butyldimethylchlorosilane according to the procedure of Corey, E.J., et al, in J Am Chem Soc (1972) 94:6190. The reaction was stirred at room temperature for 24 hours and combined with 750 ml Et₂O. The biphasic solution was washed with H₂O (3 x 250 ml). The organic layer was dried with MgSO₄, gravity filtered, and evaporated to dryness for a quantitative yield (110 g) of a colorless oil. Thin-layer chromatography showed a spot on SiGF (10% EtOAc in CHCl₃ visualization with 2% phosphomolybdic acid plus heat) at Rf 0.44 with trace impurity at Rf 0.61. ¹H NMR (CDCl₃): δ 0.10 and 0.13 (s, s, 5H), 0.97 (s, 9H), 1.33 (tr, 6H), 4.20 (dq, 4H), 4.57 (dd, 1H), 5.10-5.63 (m, 2H), 5.87-6.34 (m, 1H).

B. Preparation of Diethyl 1-t-butyldimethylsilyloxy-3-hydroxypropyl phosphate.

Diethyl 1-t-butyldimethylsilyloxyallyl phosphonate (76 g, 0.247 mole) was azeotroped from toluene three times and dissolved in 400 ml dry THF. 1 M diborane in THF (150 ml) was added dropwise at 25°C over 45 minutes and the reaction then stirred an additional 1 hour. The hydroboration was terminated by addition of 65 ml H₂O maintaining the temperature at 20°C with ice cooling. 3 N NaOH (20 ml) was added followed by dropwise addition of 80 ml 30% H₂O₂ with ice cooling to keep temperature at 40°C. The pH was checked intermittently and, when no longer alkaline, another 20 ml plus 10 ml 3 N NaOH was added in 2 portions. After addition of H₂O₂, the reaction was maintained at 35°C for an additional 20 minutes. EtOH (40 ml) was added to

-33-

improve miscibility. The reaction was poured into 800 ml Et₂O; 300 ml H₂O plus 25 ml solid NaCl was added, stirred well, and placed in the refrigerator overnight. The layers were separated and the Et₂O layer was washed
5 thoroughly with H₂O saturated with NaCl to minimize emulsions. The Et₂O solution was dried with MgSO₄, filtered, and evaporated to yield 70.25 g (87%) yellow oil. Thin-layer chromatography on SiGF (EtOAc, 5% phosphomolybdic acid plus heat) showed two spots at R_f
10 0.35 and 0.55 in approximately 2:3 ratio. In a previous synthesis, the material at R_f 0.55 was identified as the secondary alcohol and the material at R_f 0.35 as the primary alcohol. ¹H NMR (CDCl₃) δ 0.083 and 0.113 (s, s, 3H, 3H, -Si(CH₃)₂), 0.882 (s, 9H, SiC(CH₃)₃), 1.314
15 and 1.317 (tr, tr, 6H, -P(OCH₂CH₃)₂), 1.9-2.1 (m, 2H, HOCH₂CH₂-), 3.69 and 3.87 (ddq, dq, 2H, HOCH₂-), 4.07-4.22 (m, 5H, -POCH₂CH₃ and -CHPO-). In order to enhance chromatographic separation of the two alcohols, the crude material was tritylated according to the
20 procedure of Chaudhary et al, Tet. Letters (1979) 95. The mixture of tritylated alcohols were separated on silica eluting with increments of CH₂Cl₂, 10%, 30%, and 50% EtOAc in CH₂Cl₂, and finally EtOAc. TLC on SiGF (10% EtOAc in CH₂Cl₂) of the tritylated primary alcohol
25 showed R_f 0.6. The trityl group was removed instantaneously at 0°C with 1% HCl in CHCl₃ according to the procedure of Choy and Unrau, Carbohydrate Res. (1971) 17:439. Silica chromatography eluting with CH₂Cl₂, 10% EtOAc in CH₂Cl₂, and EtOAc provided 6.6 g of
30 diethyl 1-t-butyltrimethyl-silyloxy-3-hydroxypropyl phosphonate.

-34-

C. Preparation of 6-Chloro-9(3'-diethyl phosphono-3'-t-butyl
dimethylsilyloxy-1'-propyloxymethyl)guanine.

The coupling of (0.020 mole) diethyl 1-t-butyl
dimethylsilyloxy-3-chloromethoxypropyl phosphonate and
5 6-chloroguanine was conducted according to the procedure
set forth for 6-chloro-9(3'-diethyl phosphono-1'
-propyloxy methyl)guanine in Example 1. Silica
chromatography eluting with 10:1 EtOAc:iPrOH afforded
2.5 g (26%) white solid, R_f 0.79, mp 120-123°C. ¹H NMR
10 (CDCl₃) δ 0.03 and 0.14 (s, s, 6H), 0.91 (s, 9H), 1.35
and 1.38 (tr, tr, 6H), 1.77-2.32 (m, 2H), 3.64 (tr, 2H),
3.88-4.27 (m, 5H), 5.24 (br s, 2H), 5.45 (s, 2H), 7.94
(s, 1H).

15 D. Preparation of 6-Chloro-9(3'-diethylphosphono-3'-
hydroxy-1'-propyloxymethyl)guanine.

The t-butyl dimethylsilyl group was removed
from 1.62 g (3.4 mmol)
6-chloro-9(3-diethylphosphono-3'-t-butyl dimethylsilyloxy
20 -1'-propyloxymethyl)guanine in 30 ml dry THF by addition
of 3.75 ml 1 M tetrabutylammonium fluoride at 5°C.
After stirring 22 minutes at 5°C, the reaction was
evaporated to dryness and chromatographed in silica
eluting with 1:1 EtOAc:iPrOH. 6-Chloro-9(3'-diethyl-
25 phosphono-3'-hydroxy-1'-propyloxymethyl)guanine was
obtained by evaporation of the appropriate fractions and
crystallization from EtOAc to yield 0.95 g (71%) white
solid, mp 116-118°C. Thin-layer chromatography on SiGF
(10:1 EtOAc · iPrOH) showed R_f 0.21. Microanalysis
30 confirmed the formula (C₁₃H₂₁ClN₅O₅P). Calc: C-39.65%,
H-5.38%, N-17.79%. Found: C-39.59%, H-5.54%, N-17.32%.
¹H NMR (CDCl₃): δ 1.31 (tr), 1.82-2.15 (m), 3.65-3.85
(m), 3.92-4.42 (m), 5.46 (s), 5.59 (brs), 7.85 (s). UV
λ_{max}: 245, 306.

-35-

E. Conversion to Monoester and Dehalogenation

The hydrolysis of 0.645 g (1.64 mmol) of 6-chloro-9(3'-diethyl phosphono-3'-hydroxy-1'-propyloxymethyl)guanine with 32.5 ml 1 N NaOH was conducted as set forth in Example 3 for the synthesis of 9(3'-ethyl phosphono-1'-propyloxymethyl)guanine. DEAE-Sephadex chromatography yielded 35 mg (6%) material with R_f 0.48 on SiGF (7:3 CH₃CN: 0.1 N NH₄Cl). ¹H NMR (D₂O): δ 1.31 (tr), 1.72-2.20 (m), 3.76-4.1 (m), 5.68 (s). UV λ_{max} : pH 1 256, 278 shoulder; pH 7 251, 270 shoulder; pH 11 255, 265 shoulder. Mass spectrum m/e 635 (M⁺ for TMS₁ derivative).

Example 11

Using the procedures described above, the following compounds of the invention were prepared.

-36-

Table 1

	<u>Compound #</u>	<u>B</u>	<u>R1</u>	<u>R2</u>	<u>n</u>	<u>Form</u>
5	1	G	H	H	1	phosphonic acid
	2	G	H	H	1	monoethylester
	3	G	H	H	1	diethyl ester
	4	G	H	H	1	monoethyl ester, monosodium salt
10	5	G	CH ₂ OH	H	1	monoethyl ester
	6	G	CH ₂ OH	H	1	phosphonic acid
	7	G	CH ₃	H	1	monoethyl ester
	8	G	H	H	5	monoethyl ester
15	9	G	CH ₂ OH cyclic structure 1a	H	1	phosphonic acid
	10	*	H	H	1	diethyl ester
	11	*	H	H	5	diethyl ester
	12	**	H	H	1	monoethyl ester
20	13	***	H	H	1	monoethyl ester
	14	G	H	OH	1	monoethyl ester
	15	*	CH ₂ OH	H	1	diethyl ester (acetoxy ester)
	16	*	H	OH	1	diethyl ester

* 6-chloroguanine(6-chloro-2-aminopurine).

** 8-bromoguanine.

30 *** 2-NH₂-adenine (2,6-diaminopurine).F. Biological Testing

The compounds of the invention were evaluated
in vitro as antiviral agents against herpes virus and

-37-

against RNA retrovirus. Various herpes strains were used. An infected B lymphoblastoid cell line was used as HIV substrate to test antiviral activity with respect to RNA retrovirus.

5

Activity Against Herpes-Type Virus

One herpes virus strain employed was Strain McCrae of type 1 herpes (thymidine kinase positive virus) (HSV-1TK⁺). This strain was prepared and titered in MA-104 cells and frozen at -90°C until use. Also used were strain HF (HSV-1TK⁻), strain E194 (HSV-2), NJB strain (MCMV), strain AD169 (HCMV).

Continuous passaged monkey kidney (MA-104) cells were used for testing of herpes-type virus, with growth medium consisting of Minimum Essential Medium (MEM) supplemented with 0.1% NaHCO₃ and 50 µl gentamicin.

To a 96 well microtiter plate containing an established 24 hour monolayer of cells from which the medium has been decanted was added 0.1 ml of varying (one-half log₁₀) concentrations of test compound, which incubated on the cell 15 minutes, after which 0.1 ml of virus in a concentration of 320 cell culture 50% infectious doses (CCID₅₀)/0.1 ml was added. The plate was covered with plastic wrap and incubated at 37°C. Included with the test were toxicity controls (each concentration of compound + test medium in place of virus), virus controls (virus + test medium in place of compound) and cell controls (test medium in place of compound and virus). The cells were examined microscopically after 72 hours for evidence of cytotoxicity and for viral cytopathic effect (CPE). Vidarabine was run on the same plate in parallel. The test compounds were added to the medium at a

-38-

concentration of 2000 µg/ml for use as a positive control.

Antiviral activity was determined by observation of inhibition of viral CPE. This activity was expressed by ED₅₀, defined as that dose range of compound causing 50% CPE inhibition.

A Virus Rating (VR) was also determined. VR is a numerical expression of antiviral activity, weighted to take into account any cytotoxicity observed, as discussed by Sidwell et al, Appl Microbiol (1971) 22:797. Generally, a VR of 0.1-0.4 indicates slight antiviral effect, 0.5-0.9 indicates moderate antiviral effect, and \geq 1.0 indicates strong antiviral effect.

The results of the foregoing assays are as follows: The activities of compounds 1 and 2, (9-(3'-phosphono-1'-propoxymethyl)guanine and its monoethyl ester), against HSV-1TK⁺ were comparable to that of vidarabine, as shown in Tables 2 and 3.

Table 2

Anti HSV-1TK⁺ Activity

<u>Compound 1</u>		<u>Vidarabine</u>	
<u>Conc.</u> <u>(µg/ml)</u>	<u>CPE</u> <u>Inhib.</u> <u>(%)</u>	<u>Conc.</u> <u>(µg/ml)</u>	<u>CPE</u> <u>Inhib.</u> <u>(%)</u>
1000	100	1000	100
320	94	320	100
100	79	100	87
32	62	32	87
10	49	10	69
3.2	28	3.2	28
1.0	31	1.0	56
VR	1.4	1.3	
ED ₅₀	10 µg/ml	10 µg/ml	

-39-

An additional test of Compound 1 gave VR against HSV-1TK⁺ of 0.6; this compound was not active against murine CMV.

5

Table 3

Anti HSV-1TK⁺ Activity

	Compound 2			Vidarabine		
	Conc. ($\mu\text{g/ml}$)	Test 1 CPE Inhib. (%)	Test 2 CPE Inhib. (%)	Conc. ($\mu\text{g/ml}$)	Test 1 CPE Inhib. (%)	Test 2 CPE Inhib. (%)
10	1000	100	76	1000	100	100
	320	82	67	320	100	100
	100	47	57	100	96	85
	32	6	57	32	96	57
	10	38	48	10	60	39
	3.2	96	52	3.2	2	0
	1.2	69	48	1.0	0	0
15	1000	100	76	1000	100	100
	320	82	67	320	100	100
	100	47	57	100	96	85
	32	6	57	32	96	57
	10	38	48	10	60	39
	3.2	96	52	3.2	2	0
	1.2	69	48	1.0	0	0
20	1000	100	76	1000	100	100
	320	82	67	320	100	100
	100	47	57	100	96	85
	32	6	57	32	96	57
	10	38	48	10	60	39
	3.2	96	52	3.2	2	0
	1.2	69	48	1.0	0	0
25	VR	>2.0	>1.4		0.8	0.7
	ED ₅₀	<1.0 $\mu\text{g/ml}$	<1.0 $\mu\text{g/ml}$		10 $\mu\text{g/ml}$	10 $\mu\text{g/ml}$
	MTD	320	>1000		10	10

*Maximum tolerated dose, $\mu\text{g/ml}$.

Additional tests of Compound 2 against HSV-1TK⁺ showed VR values of 0.4, 0.6, 0.9, 0.4, 0.3, and 0.7. Compound 2 was active against murine CMV (VR = 0.6, 1.6, 2.3) and human CMV (ED₅₀ = 10 $\mu\text{g/ml}$).

Compound 5 (9-(3'-phosphono-1'-hydroxy-methylpropoxymethyl) guanine, monoethyl ester, showed an

30

-40-

ED₅₀ of 0.1-3.2 µg/ml against human CMV. It was mildly effective against HSV1TK⁺ and HSV-2.

Compound 2 also was tested in vivo in guinea pigs as an agent against HSV-1TK⁺. The animals were inoculated with the virus; 18 hours later Compound 2 at two concentrations (0.4% and 1-2% (saturated) solution in water) was administered, and five days later blister diameters at the point of inoculation were measured. A 5% solution of acyclovir or a 1.4% solution of poly(vinylalcohol) was used as control. Satellite lesions were measured, as well.

The results of these tests are given as average number of lesions in Table 4 and show that Compound 2 has activity against HSV TK⁺ virus, at least in saturated solution.

Table 4

Virus	Placebo	Acyclovir	Compound 2	Compound 2
	poly(Vinylalcohol)		1-2%	0.4%
TK ⁺	1.7	1.0	0.9	2.1
Satellite lesions	9	4	6	11

Table 5 shows the results of two experiments showing the antiviral activity of compounds 2 and 5 against human cytomegalovirus.

30

-41-

Table 5

Compound Concentration ($\mu\text{g/ml}$)	Compound 2		Compound 5		Acyclovir	
	No.	%	No.	%	No.	%
	Plaques	Reduct.	Plaques	Reduct.	Plaques	Reduct.
5	<u>Experiment</u>					
	<u>No. 1</u>					
100	0	100	1	94	1	94
32	5	71	2	88	7	59
0	17	-	17	-	17	-
	Approx. ED50 ^a					
10	($\mu\text{g/ml}$):	10	0.1		10-32	
	<u>Experiment</u>					
	<u>No. 2</u>					
100	1	96	0	100	1	96
32	6	73	3	86	8	64
10	17	23	7	68	20	9
15	0	22	22	-	22	-
	Approx. ED50					
	($\mu\text{g/ml}$):	10-32	3.2		10-32	
	Approx. MTD ^b : 1000					
			1000		1000	

20 ^a50% effective dose, determined from plot of data.

^bMaximum tolerated dose: That dose causing approximately 50% cytotoxic effects in cells, determined by the microscopic examination of cells for sloughing, shape alteration, and granularity in separately run control tests in 96-well microplates.

25

The data on acyclovir were gathered from tests run in MRC-5 cells grown under agarose overlay, with plaques read 7 days after virus exposure. Overall, the data in Table 5 show that compound 1 and acyclovir appear to have approximately the same human CMV-inhibitory effects and cytotoxicity. Compound 5 appears to have a more potent anti-CMV effect than acyclovir, and to be no more cytotoxic.

30

-42-

Activity Against RNA Retrovirus

The ability of compounds of the invention to exhibit antiviral activity against RNA retroviruses was shown in an in vitro assay similar to that described above and was also demonstrated by their ability to inhibit reverse transcriptase.

For the reverse transcriptase assay, cloned reverse transcriptase (RT) (Bethesda Research Laboratories) from Moloney murine leukemia virus (MMLV) or avian myeloblastosis virus (AMV) (Seikagaku or Boehringer Mannheim) was used to direct DNA synthesis from a polyribonucleotide template and a oligodeoxynucleotide primer under reaction conditions (Houts, G.E., et al, J Viro (1979) 29:517.)

Reaction mixtures (100 μ l) for the assay of MMLV RT consisted of 50 mM Tris-hydrochloride, pH 8.0, 6 mM $MgCl_2$, 40 mM KCl, 100 μ g bovine serum albumin per ml, 1 mM dithiothreitol, 0.1 mM polyadenylic acid (Pharmacia, Inc.), 0.1 mM oligo(dT)₁₂₋₁₈ (Pharmacia, Inc.), 0.4 mM deoxythymidine triphosphate (dTTP), and 0.1 mM tritiated (93.5 Ci/mmol) dTTP (New England Nuclear). The compounds assayed were added in various concentrations and dilutions at a volume of 10 μ l. Results were confirmed by duplicate assays. Dilutions were made using 10% aqueous DMSO. The total activity was measured by spotting on dry Whatman 3 mm filter disks and radioactivity was determined by liquid scintillation techniques. The assay time course was begun by adding 10 units of RT from MMLV or AMV and incubating the reaction at 37°C. Aliquots (10 μ l) were removed as a function of time and quenched in 20 μ l of stop mix [0.25 mM EDTA, 0.5 mg/ml yeast tRNA (BDH Biochemicals, England), 10 mM sodium pyrophosphate]. The 30 μ l samples were spotted onto Whatman 3 mm disks and

-43-

batch-washed (10 ml/disk) in ice-cold 10% TCA, 1% sodium pyrophosphate for 10 minutes with agitation. This was followed by three 4 minute ice-cold 5% TCA batch washes and a final 95% ethanol rinse (1 minute). Disks were
5 dried under a heat lamp and the acid-insoluble product radioactivity was determined by liquid scintillation counting. Blank assays were conducted using 10% DMSO. Phosphonoformic acid, trisodium salt (Sigma Chemical Company), dissolved in water was used as a positive
10 control at a final concentration of 1 mM.

To test antiviral activity versus HIV, the following procedure was used: Infectious HIV was assayed in cell culture as described originally by Barre-Sinoussi et al for isolation of LAV, except that
15 persistently infected lymphoblastoid cells were used instead of mononuclear cells from anti-LAV negative donors. HIV obtained from cell culture was stored in liquid nitrogen in aliquots of RPMI 1640 culture medium with 20% of total calf serum and 20% glycerol and
20 containing 1,000 TCID-50 HIV. The lymphoblastoid cells (10^6) were incubated with 1,000 TCID-50 of HIV obtained from cell cultures, and cells were then cultured in RPMI-1640 medium. Culture medium was changed every 3
25 days for 3 weeks and the medium for each 3-day period from Day 6 through Day 21 was assayed for viral reverse transcriptase activity by concentrating (pelleting) virus by ultracentrifugation in the 100 place Spinco 25
rotor and assaying pellets for reverse transcriptase (RT) using a ^{32}P -dTTP in the presence of dimer-template
30 poly rA-oligo dT. Compounds to be tested for neutralization of infection were incubated with HIV aliquots (10^3 TCID-50) for 30 minutes at 22°C before incubation with 10^6 lymphoblastoid cells.

-44-

The results obtained in the foregoing assays were as follows: Compound 1, 9-(3-phosphono-1-propoxy methyl)guanine, showed 75% inhibition of reverse transcriptase at 8 mM concentration; compound 2, the
5 monoethyl ester form, showed 100% inhibition at 1 mM. These activities were further reflected in ED₅₀ values against HIV, which were 40-50 µg/ml and 30µg/ml, respectively.

10 G. Formulations

The following formulations based on the compounds of the invention and their preparation are representative.

15 A formulation suitable for injections intramuscularly or intraperitoneally is prepared by combining the first four of the following materials:

	Compound of the invention	1 g
	Poly(ethylene glycol)	50 g
20	Propylene glycol	50 g
	Tween-80 suspension agent	1.5 g
	Injectable saline	200 ml

25 and then adding the last material. The material forms a clear solution which is filtered and sealed in sterile containers.

A simple intravenous injection formulation is formed by dissolving 1 gram of an active compound in 250 ml of injectable saline which after filtering is
30 packaged in sterile bottles.

A cream for topical administration is formulated by stirring 10 g of active compound of the invention with 20 g of mineral oil, 40 g of petroleum jelly, 0.3 g of mixed methyl/propyl paraben, and 5 g of

-45-

nonionic surfactant at 50°C. Then 150 ml of water are stirred into the mixture at 50°C at high speed to form a cream, and the mixture is cooled and packaged in capped tubes.

5 An oral dosage form is prepared from 10 g of a compound of the invention, 100 g of lactose, and 1 g of starch, which are mixed with 0.1 g of magnesium stearate in methanol to granulate. The methanol is removed by gentle heating with stirring. A portion of this
10 material is retained as a granular powder for oral use while the remainder is hand formed into 250 mg tablets in a manual tableting machine.

15 The foregoing examples and formulations have been presented to illustrate the present invention and are not to be construed as limitations on the invention's scope, which is instead defined by the following claims.

20


25

30

-46-

WHAT IS CLAIMED IS:

1. A compound of the formula



wherein B is a substituted or unsubstituted purine base conjugated to the remainder of the structure through the 9-position,


R1 is selected from H, methyl, hydroxymethyl and its lower alkyl esters, halomethyl, azidomethyl and cyano;

R2 is selected from H, methyl, hydroxymethyl and its lower alkyl esters, halomethyl, azidomethyl, cyano and OH and its lower alkyl esters; or R2 and the H residing in the same carbon are, together, =O; and

n is an integer of 0-5,

and the pharmaceutically acceptable acid addition salts, mono- and dibasic salts, and mono- and diesters thereof,

or wherein, when n is 0 or 1 and R1 is CH₂OH, the compound of Formula 1 has the formula



wherein B and R2 are as above defined, and the pharmaceutically acceptable acid addition salts, monobasic salts, and monoesters thereof.

-47-

2. The compound of claim 1 wherein B is selected from guanine, 8-haloguanine, adenine, 8-haloadenine, 2-hydroxy-6-halopurine, and 2-amino-6-halopurine (6-haloguanine), 2-aminopurine and 2,6-diaminopurine.


3. The compound of claim 1 wherein the phosphonic acid ester or diester is the alkyl (1-8C) ester or diester.

4. The compound of claim 3 which is selected from the free phosphonic acid, the phosphonic acid monoethyl ester, and the phosphonic acid diethyl ester.

5. The compound of claim 1 wherein R1 is selected from H, CH₃, and CH₂OH, and R2 is H or OH.

6. The compound of claim 1 wherein n is 1 or 2.

7. The compound of claim 1 which has the formula



and the pharmaceutically acceptable acid addition salts, monobasic salts and mono esters thereof.

8. The compound of claim 6 wherein B is guanine or 6-haloguanine.

-48-

9. The compound of claim 1 wherein B is guanine, R1 and R2 are H, and n is 1 as the phosphonic acid, monoethyl ester, diethyl ester, or monoethyl ester/monosodium salt

5

10. The compound of claim 1 wherein B is guanine, R1 and R2 are H, and n is 5 as the phosphonic acid, monoethyl ester, diethyl ester, or monoethyl ester/monosodium salt

10

11. The compound of claim 4 which is selected from the group consisting of:

- 15 6-chloro-9(3'-diethylphosphono-1'-propyloxymethyl) guanine;
9(3'-diethylphosphono-1'-propyloxymethyl) guanine;
9(3'-ethylphosphono-1'-propyloxymethyl)guanine;
9(3'-phosphono-1'-propyloxymethyl)guanine;
20 9(3'-ethylphosphono-1'-propyloxymethyl)guanine, monosodium salt;
6-chloro-9(7'-diethylphosphono-1'-heptyloxymethyl) guanine;
9(7'-ethylphosphono-1'-heptyloxymethyl)guanine;
25 9(3'-ethylphosphono-1'-hydroxymethyl-1'-propyloxymethyl) guanine;
6-chloro-9(3'-diethylphosphono-1'-acetoxymethyl-1'-propyloxymethyl)guanine;
9(3'-phosphono-1'-hydroxymethyl-1'-propyloxymethyl) guanine;
30 9(3'-ethylphosphono-1'-methyl-1'-propyloxymethyl) guanine;
9(3'-phosphono-1'-hydroxymethyl-1'-propyloxymethyl) guanine, cyclic ester;

-49-

9(3'-ethylphosphono-3'-hydroxy-1'-propyloxymethyl)
guanine;

6-chloro-9(3'-diethylphosphono-3'-hydroxy-1'-
propyloxymethyl)guanine;

5 8-bromo-9(3'-ethylphosphono-1'-propyloxymethyl)guanine;
and

2-amino-9(3'-ethylphosphono-1'-propyloxymethyl)adenine.

12. A pharmaceutical composition for treating
10 herpes viral infection which comprises an effective
amount of the compound of claim 1 in admixture with a
suitable pharmaceutically acceptable excipient.

13. A method to treat herpes infection in an
15 infected subject which comprises administering to said
subject an effective amount of the compound of formula 1
or pharmaceutical compositions thereof.

14. A pharmaceutical composition for treating
20 an RNA retroviral infection which comprises an effective
amount of the compound of claim 1 in admixture with a
suitable pharmaceutically acceptable excipient.


15. A method to treat an RNA retroviral
25 infection in an infected subject which comprises
administering to said subject an effective amount of the
compound of formula 1 or pharmaceutical compositions
thereof.

30

AMENDED CLAIMS

[received by the International Bureau on 11 July 1988 (11.07.88)
original claim 11 cancelled; claim 1 amended; new claims 16-53 added (9 pages)]

1. A compound of the formula



wherein B is a purine base conjugated to the remainder of the structure through the 9-position,


R1 is selected from H, methyl, hydroxymethyl and its lower alkyl esters, halomethyl, azidomethyl and cyano;

R2 is selected from H, methyl, hydroxymethyl and its lower alkyl esters, halomethyl, azidomethyl, cyano and OH and its lower alkyl esters; or R2 and the H residing in the same carbon are, together, =O; and

n is an integer of 0-5,

and the pharmaceutically acceptable acid addition salts, mono- and dibasic salts, and mono- and diesters thereof,

or wherein, when n is 0 or 1 and R1 is CH₂OH, the compound of Formula 1 has the formula



wherein B and R2 are as above defined,

and the pharmaceutically acceptable acid addition salts, monobasic salts, and monoesters thereof.

9. The compound of claim 1 wherein B is
guanine, R1 and R2 are H, and n is 1 as the phosphonic
acid, monoethyl ester, diethyl ester, or monoethyl
ester/monosodium salt

5

10. The compound of claim 1 wherein B is
guanine, R1 and R2 are H, and n is 5 as the phosphonic
acid, monoethyl ester, diethyl ester, or monoethyl
ester/monosodium salt

10

[Claim 11 canceled.]

15

20

25

30

[Claim 11 canceled (continued).]

5

12. A pharmaceutical composition for treating
herpes viral infection which comprises an effective
amount of the compound of claim 1 in admixture with a
suitable pharmaceutically acceptable excipient.

10

13. A method to treat herpes infection in an
infected subject which comprises administering to said
subject an effective amount of the compound of formula 1
or pharmaceutical compositions thereof.

15

14. A pharmaceutical composition for treating
an RNA retroviral infection which comprises an effective
amount of the compound of claim 1 in admixture with a
suitable pharmaceutically acceptable excipient.

20

15. A method to treat an RNA retroviral
infection in an infected subject which comprises admin-
istering to said subject an effective amount of the com-
pound of formula 1 or pharmaceutical compositions
thereof.

25

30

16. (New claim) The compound of claim 4 which is selected from the group consisting of:

2-amino-6-chloro-9-(3'-diethylphosphono-1'-propyloxymethyl) purine;

5 9(3'-diethylphosphono-1'-propyloxymethyl) guanine;

9(3'-ethylphosphono-1'-propyloxymethyl) guanine;

10 9(3'-ethylphosphono-1'-propyloxymethyl) guanine, monosodium salt;]

2-amino-6-chloro-9(3'-diethylphosphono-1'-heptyl-oxymethyl) purine;

9(3'-ethylphosphono-1'-heptyloxymethyl) guanine;

15 2-amino-6-chloro-9(3'-diethylphosphono-1'-acetoxy-methyl-1'-propyloxymethyl) purine;

9(3'-phosphono-1'-hydroxymethyl-1'-propyloxy-methyl) guanine;

20 9(3'-ethylphosphono-1'-methyl-1'-propyloxy-methyl) guanine;

9(3'-ethylphosphono-3'-hydroxy-1'-propyloxy-methyl) guanine;

2-amino-6-chloro-9(3'-diethylphosphono-3'-hydroxy-1'-propyloxymethyl) purine;

25 6-bromo-9(3'-ethylphosphono-1'-propyloxy-methyl) guanine; and

2-amino-9(3'-ethylphosphono-1'-propyloxy-methyl) adenine.

30 17. (New claim) The compound of claim 1, given by formula (1), wherein R₁ is H and either R₂ is H or R₂ and the H residing in the same carbon are, together =O, and the pharmaceutically acceptable acid addition salts, monobasic salts, and monoesters thereof.

18. (New claim) The phosphonic acid mono ester
of the compound of claim 1, wherein the ester is 1-8C
alkyl, phenyl or benzyl, optionally substituted with one
or two halo, hydroxy, or alkoxy residues.

19. (New claim) The phosphonic acid mono ester
of the compound of claim 7, wherein the ester is 1-8C
alkyl, phenyl or benzyl, optionally substituted with one
or two halo, hydroxy, or alkoxy residues.

20. (New claim) The phosphonic acid mono ester
of the compound of claim 17, wherein the ester is 1-8C
alkyl, phenyl or benzyl, optionally substituted with one
or two halo, hydroxy, or alkoxy residues.

21. (New claim) The phosphonic acid mono ester
of the compound of claim 18, wherein the ester is 1-6C
alkyl, optionally substituted with one or two halo,
hydroxy, or alkoxy residues.

22. (New claim) The phosphonic acid mono ester
of the compound of claim 19, wherein the ester is 1-6C
alkyl, optionally substituted with one or two halo,
hydroxy, or alkoxy residues.

23. (New claim) The phosphonic acid mono ester
of the compound of claim 20, wherein the ester is 1-6C
alkyl, optionally substituted with one or two halo,
hydroxy, or alkoxy residues.

24. (New claim) The phosphonic acid of claim
7.

25. (New claim) The compound of claim 1 which is selected from the group consisting of 9(3'-phosphono-1'-propyloxymethyl) guanine, 9(3'-ethylphosphono-1'-propyloxymethyl) guanine monosodium salt, 9(3'-ethylphosphono-1'-propyloxymethyl) guanine ammonium salt, 9(3'-ethyl-phosphono-1'-hydroxymethyl-1'-propyloxymethyl) guanine, and 9(1',3'-phosphono-1'-hydroxymethyl-1'-propyl-oxymethyl) guanine cyclic ester.

26. (New claim) The compound of claim 1 which is 9(3'-phosphono-1'-propyloxymethyl) guanine.

27. (New claim) The compound of claim 1 which is 9(3'-ethylphosphono-1'-propyloxymethyl) guanine, monosodium salt.

28. (New claim) The compound of claim 1 which is 9(3'-ethylphosphono-1'-hydroxymethyl-1'-propyloxy-methyl) guanine.

29. (New claim) The compound of claim 1 which is 9(1',3'-phosphono-1'-hydroxymethyl-1'-propyloxy-methyl) guanine, cyclic ester.

30. (New claim) The compound of claim 1 which is 9(3'-methylphosphono-1'-propyloxymethyl) guanine.

31. (New claim) The compound of claim 1 which is 9(3'-butylphosphono-1'-propyloxymethyl) guanine.


32. (New claim) The compound of claim 1 which is 9(3'-benzylphosphono-1'-propyloxymethyl) guanine.

33. (New claim) The compound of claim 1 which is 9(3'-phenylphosphono-1'-propyloxymethyl) guanine.

34. (New claim) The compound of claim 1 which is 9[3'-(p-methoxyphenylphosphono)-1'-propyloxymethyl] guanine.

35. (New claim) The compound of claim 1 which is 9(3'-ethylphosphono-3'-hydroxy-1'-propyloxymethyl) guanine.

36. (New claim) The compound of claim 1 which is given by the structure



where n is 0, 2, 3, 4, or 5.

37. (New claim) The compound of claim 36 which is 9(2'-ethylphosphono-1'-ethyloxymethyl) guanine.

38. (New claim) The compound of claim 36 which is 9(4'-ethylphosphono-1'-butyloxymethyl) guanine.

39. (New claim) The compound of claim 36 which is 9(5'-ethylphosphono-1'-pentyloxymethyl) guanine.

40. (New claim) The compound of claim 36 which is 9(6'-ethylphosphono-1'-hexyloxymethyl) guanine.

41. (New claim) The compound of claim 36 which is 9(7'-ethylphosphono-1'-heptyloxymethyl) guanine.

5 42. (New claim) A pharmaceutical composition for treating herpes viral infection which comprises an effective amount of the compound of claim 7.

10 43. (New claim) A method to treat herpes infection in an infected subject which comprises administering to said subject an effective amount of the compound of claim 7 or pharmaceutical compositions thereof.

15 44. (New claim) A pharmaceutical composition for treating an RNA retrovirus which comprises an effective amount of the compound of claim 7.

20 45. (New claim) A method to treat an RNA retrovirus infection in an infected subject which comprises administering to said subject an effective amount of the compound of claim 7 or pharmaceutical compositions thereof.

25 46. (New claim) The pharmaceutical composition of claim 44, wherein the RNA retrovirus is HIV.

 47. (New claim) The method of claim 45, wherein the RNA retrovirus is HIV.

30 48. (New claim) A pharmaceutical composition for treating herpes viral infection which comprises an effective amount of the compound of claim 17.

49. (New claim) A method to treat herpes
infection in an infected subject which comprises admin-
istering to said subject an effective amount of the com-
pound of claim 17 or pharmaceutical compositions
thereof.

50. (New claim) A pharmaceutical composition
for treating an RNA retrovirus infection which comprises
an effective amount of the compound of claim 17.

51. (New claim) A method to treat an RNA
retrovirus infection in an infected subject which com-
prises administering to said subject an effective amount
of the compound of claim 17 or pharmaceutical composi-
tions thereof.

52. (New claim) The pharmaceutical composition
of claim 50, wherein the RNA retorvirus is HIV.

53. (New claim) The method of claim 51,
wherein the RNA retrovirus is HIV.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 87/03446

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ¹ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : C 07 F 9/65; A 61 K 31/675														
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-bottom: 1px solid black;">Classification System ¹</td> <td style="width: 70%; border-bottom: 1px solid black;">Classification Symbols</td> </tr> <tr> <td style="height: 40px; vertical-align: top; border: 1px solid black;">IPC⁴</td> <td style="height: 40px; vertical-align: top; border: 1px solid black;">C 07 F 9/00</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System ¹	Classification Symbols	IPC ⁴	C 07 F 9/00								
Classification System ¹	Classification Symbols													
IPC ⁴	C 07 F 9/00													
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category ⁹</th> <th style="width: 70%; border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; border: 1px solid black;">X</td> <td style="border: 1px solid black;"> Antiviral Research, volume 6, 1986, Elsevier Science Publishers B.V. (Biomedical Division), A.E. Duke et al.: "In vitro and in vivo activities of phosphate derivatives of 9-(1,3-dihydroxy-2- propoxymethyl)-guanine against cytomegaloviruses", pages 299-308 see the whole document <div style="text-align: center;">--</div> </td> <td style="text-align: center; vertical-align: top; border: 1px solid black;">1-15</td> </tr> <tr> <td style="text-align: center; vertical-align: top; border: 1px solid black;">X</td> <td style="border: 1px solid black;"> Journal of Medicinal Chemistry, volume 29, no. 5, May 1986, American Chemical Society, (US), E.J. Prisbe et al.: "Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl] guanine", pages 671-675 see the whole document cited in the application <div style="text-align: center;">--</div> </td> <td style="text-align: center; vertical-align: top; border: 1px solid black;">1-15</td> </tr> <tr> <td style="text-align: center; vertical-align: top; border: 1px solid black;">X</td> <td style="border: 1px solid black;"> EP, A, 0173624 (MERCK & CO.) 5 March 1986 see the whole document </td> <td style="text-align: center; vertical-align: top; border: 1px solid black;">1-15</td> </tr> </table> <div style="margin-top: 10px;"> <div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div> </div>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	Antiviral Research, volume 6, 1986, Elsevier Science Publishers B.V. (Biomedical Division), A.E. Duke et al.: "In vitro and in vivo activities of phosphate derivatives of 9-(1,3-dihydroxy-2- propoxymethyl)-guanine against cytomegaloviruses", pages 299-308 see the whole document <div style="text-align: center;">--</div>	1-15	X	Journal of Medicinal Chemistry, volume 29, no. 5, May 1986, American Chemical Society, (US), E.J. Prisbe et al.: "Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl] guanine", pages 671-675 see the whole document cited in the application <div style="text-align: center;">--</div>	1-15	X	EP, A, 0173624 (MERCK & CO.) 5 March 1986 see the whole document	1-15
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X	Antiviral Research, volume 6, 1986, Elsevier Science Publishers B.V. (Biomedical Division), A.E. Duke et al.: "In vitro and in vivo activities of phosphate derivatives of 9-(1,3-dihydroxy-2- propoxymethyl)-guanine against cytomegaloviruses", pages 299-308 see the whole document <div style="text-align: center;">--</div>	1-15												
X	Journal of Medicinal Chemistry, volume 29, no. 5, May 1986, American Chemical Society, (US), E.J. Prisbe et al.: "Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl] guanine", pages 671-675 see the whole document cited in the application <div style="text-align: center;">--</div>	1-15												
X	EP, A, 0173624 (MERCK & CO.) 5 March 1986 see the whole document	1-15												
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="height: 40px; vertical-align: bottom; border: 1px solid black;">6th April 1988</td> <td style="height: 40px; vertical-align: bottom; border: 1px solid black;">09 MAY 1988</td> </tr> <tr> <td style="border-bottom: 1px solid black;">International Searching Authority</td> <td style="border-bottom: 1px solid black;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center; height: 40px; vertical-align: bottom; border: 1px solid black;">EUROPEAN PATENT OFFICE</td> <td style="text-align: center; height: 40px; vertical-align: bottom; border: 1px solid black;"> P.C.G. VAN DER PUTTEN </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	6th April 1988	09 MAY 1988	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	 P.C.G. VAN DER PUTTEN				
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report													
6th April 1988	09 MAY 1988													
International Searching Authority	Signature of Authorized Officer													
EUROPEAN PATENT OFFICE	 P.C.G. VAN DER PUTTEN													

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
------------	--	----------------------

X	cited in the application -- WO, A, 84/04748 (SRI INTERNATIONAL) 6 December 1984 see the whole document -----	1-15
---	---	------

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 8703446

SA 20473

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 26/04/88. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0173624	05-03-86	JP-A- 61057584	24-03-86
WO-A- 8404748	06-12-84	SE-A- 8500307	23-01-85
		NL-A- 8420134	01-04-85
		EP-A- 0145739	26-06-85
		GB-A, B 2150570	03-07-85
		DE-T- 3490262	28-11-85
		JP-T- 60501407	29-08-85